Condition Hub

Sexual Health & HPG Axis

Peptides affecting sexual function, libido, fertility, and the hypothalamic-pituitary-gonadal axis.

Clinical Overview

Sexual Health & HPG Axis

Peptides affecting sexual function, libido, fertility, and the hypothalamic-pituitary-gonadal axis.

1 peptide1 FDA-approvedSubcutaneous injection (SC); auto-injector available (Vyleesi)Last reviewed · April 22, 2026

Sexual-health peptides act on central and peripheral pathways governing libido, arousal, and reproductive endocrine function — from FDA-approved melanocortin agonists to HPG-axis preservation agents used alongside testosterone replacement.

Mechanism Classes

  • Melanocortin receptor agonists

    PT-141 (bremelanotide) activates central melanocortin receptors involved in sexual desire and arousal. FDA-approved for HSDD in premenopausal women.

  • GnRH & kisspeptin analogs

    Gonadorelin is a synthetic GnRH decapeptide used for pulsatile pituitary stimulation. Kisspeptin-10 is an upstream regulator of GnRH release, used primarily in research.

  • HPG-axis preservation agents

    Gonadorelin (and historically hCG as an LH analog) preserves testicular size and function during exogenous testosterone replacement by maintaining LH / FSH stimulation.

Regulatory Status

FDA-Approved

  • PT-141 / Bremelanotide (HSDD, premenopausal women)

Investigational / Off-Label

  • Kisspeptin-10
  • Gonadorelin (compounded)

PT-141 is FDA-approved for female HSDD only; off-label use in men and for other indications is common but unapproved. Gonadorelin has historical endocrinology use but the compounded form is unapproved.

Evidence Base

PT-141 has FDA-approval-grade Phase 3 data for female HSDD. Gonadorelin has decades of endocrinology literature for pulsatile GnRH replacement. Kisspeptin-10 remains primarily a research tool with emerging clinical translation.

Primary-Literature References

12

Across 1 linked monograph

Prescribing Considerations

  1. 1Screen for uncontrolled hypertension and cardiovascular disease before PT-141 (contraindications; transient BP elevation of 3–6 mmHg).
  2. 2Counsel on common PT-141 side effects: nausea, flushing, headache (typically transient).
  3. 3TRT monitoring on gonadorelin protocols: testosterone, estradiol, PSA, hematocrit.
  4. 4Distinguish agents preserving endogenous function (gonadorelin, kisspeptin) from downstream-acting agents (PT-141, testosterone itself).
  5. 5Kisspeptin-10 use outside research settings is investigational — document informed consent.
  6. 6Off-label PT-141 use in men for ED is common but not FDA-approved — ensure consent reflects off-label framing.
Peer-reviewed clinical references · last reviewed April 22, 2026PeptidePrescriber · Clinical Reference

Peptides in this category(1)

Clinical monographs for each agent — dosing ranges, safety profile, evidence, and prescribing considerations.

2 additional monographs in this category are in clinical review and will be published soon.

Get matched with a vetted compounding pharmacy

Tell us what you prescribe. We manually vet compounding-pharmacy partners for identity testing, purity, endotoxin limits, and shipping reliability. When you qualify, we introduce you directly — no cost, no sales reps.

For licensed healthcare professionals only. We don't sell your information. You control whether any introduction actually happens.

Frequently Asked Questions